EGFR and cancer: Daphne W Bell receives royalties as a co-inventor on U.S. Patent No.7,294,468 “Method to Determine Responsiveness of Cancer to Epidermal Growth Factor Receptor Targeting Treatments”, which is licensed to Esoterix Genetic Laboratories LLC.